<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.1//EN" "http://www.w3.org/TR/xhtml11/DTD/xhtml11.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>
<title>Bibliographie</title>
</head>
<body>
<div class="csl-bib-body" style="line-height: 1.35; ">
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[1]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J. Zhou, «&nbsp;Développement d’un modèle de simulation à événements discrets pour l’évaluation médico-économique des interventions de santé chez les patients atteints de schizophrénie&nbsp;», PhD Thesis, Aix-Marseille, 2020.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adissertation&amp;rft.title=D%C3%A9veloppement%20d'un%20mod%C3%A8le%20de%20simulation%20%C3%A0%20%C3%A9v%C3%A9nements%20discrets%20pour%20l'%C3%A9valuation%20m%C3%A9dico-%C3%A9conomique%20des%20interventions%20de%20sant%C3%A9%20chez%20les%20patients%20atteints%20de%20schizophr%C3%A9nie&amp;rft.aufirst=Junwen&amp;rft.aulast=Zhou&amp;rft.au=Junwen%20Zhou&amp;rft.date=2020"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[2]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">D. Tordrup <i>et al.</i>, «&nbsp;Economic burden of female genital mutilation in 27 high-prevalence countries&nbsp;», <i>BMJ global health</i>, vol. 7, n<sup>o</sup> 2, p. e004512, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Economic%20burden%20of%20female%20genital%20mutilation%20in%2027%20high-prevalence%20countries&amp;rft.jtitle=BMJ%20global%20health&amp;rft.volume=7&amp;rft.issue=2&amp;rft.aufirst=David&amp;rft.aulast=Tordrup&amp;rft.au=David%20Tordrup&amp;rft.au=Chrissy%20Bishop&amp;rft.au=Nathan%20Green&amp;rft.au=Max%20Petzold&amp;rft.au=Fernando%20Ruiz%20Vallejo&amp;rft.au=Joshua%20P%20Vogel&amp;rft.au=Christina%20Pallitto&amp;rft.date=2022&amp;rft.pages=e004512"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[3]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">D. Su, B. Wu, et L. Shi, «&nbsp;Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma&nbsp;», <i>JAMA Network Open</i>, vol. 4, n<sup>o</sup> 2, p. e210037‑e210037, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20of%20atezolizumab%20plus%20bevacizumab%20vs%20sorafenib%20as%20first-line%20treatment%20of%20unresectable%20hepatocellular%20carcinoma&amp;rft.jtitle=JAMA%20Network%20Open&amp;rft.volume=4&amp;rft.issue=2&amp;rft.aufirst=Dan&amp;rft.aulast=Su&amp;rft.au=Dan%20Su&amp;rft.au=Bin%20Wu&amp;rft.au=Lizheng%20Shi&amp;rft.date=2021&amp;rft.pages=e210037%E2%80%93e210037&amp;rft.spage=e210037&amp;rft.epage=e210037"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[4]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">T. Snowsill, «&nbsp;A new method for model-based health economic evaluation utilizing and extending moment-generating functions&nbsp;», <i>Medical Decision Making</i>, vol. 39, n<sup>o</sup> 5, p. 523‑539, 2019.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A%20new%20method%20for%20model-based%20health%20economic%20evaluation%20utilizing%20and%20extending%20moment-generating%20functions&amp;rft.jtitle=Medical%20Decision%20Making&amp;rft.volume=39&amp;rft.issue=5&amp;rft.aufirst=Tristan&amp;rft.aulast=Snowsill&amp;rft.au=Tristan%20Snowsill&amp;rft.date=2019&amp;rft.pages=523%E2%80%93539&amp;rft.spage=523&amp;rft.epage=539"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[5]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">S. K. Sherman <i>et al.</i>, «&nbsp;Cost-effectiveness of maintenance capecitabine and bevacizumab for metastatic colorectal cancer&nbsp;», <i>JAMA oncology</i>, vol. 5, n<sup>o</sup> 2, p. 236‑242, 2019.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20of%20maintenance%20capecitabine%20and%20bevacizumab%20for%20metastatic%20colorectal%20cancer&amp;rft.jtitle=JAMA%20oncology&amp;rft.volume=5&amp;rft.issue=2&amp;rft.aufirst=Scott%20K&amp;rft.aulast=Sherman&amp;rft.au=Scott%20K%20Sherman&amp;rft.au=Joel%20J%20Lange&amp;rft.au=Fadi%20S%20Dahdaleh&amp;rft.au=Rahul%20Rajeev&amp;rft.au=T%20Clark%20Gamblin&amp;rft.au=Blase%20N%20Polite&amp;rft.au=Kiran%20K%20Turaga&amp;rft.date=2019&amp;rft.pages=236%E2%80%93242&amp;rft.spage=236&amp;rft.epage=242"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[6]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">M. A. Rotondi, O. Wong, M. Riddell, et B. Perkins, «&nbsp;Population-Level Impact and Cost-effectiveness of Continuous Glucose Monitoring and Intermittently Scanned Continuous Glucose Monitoring Technologies for Adults With Type 1 Diabetes in Canada: A Modeling Study&nbsp;», <i>Diabetes Care</i>, vol. 45, n<sup>o</sup> 9, p. 2012‑2019, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Population-Level%20Impact%20and%20Cost-effectiveness%20of%20Continuous%20Glucose%20Monitoring%20and%20Intermittently%20Scanned%20Continuous%20Glucose%20Monitoring%20Technologies%20for%20Adults%20With%20Type%201%20Diabetes%20in%20Canada%3A%20A%20Modeling%20Study&amp;rft.jtitle=Diabetes%20Care&amp;rft.volume=45&amp;rft.issue=9&amp;rft.aufirst=Michael%20A&amp;rft.aulast=Rotondi&amp;rft.au=Michael%20A%20Rotondi&amp;rft.au=Octavia%20Wong&amp;rft.au=Michael%20Riddell&amp;rft.au=Bruce%20Perkins&amp;rft.date=2022&amp;rft.pages=2012%E2%80%932019&amp;rft.spage=2012&amp;rft.epage=2019"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[7]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">C. Rothery <i>et al.</i>, «&nbsp;Value of information analytical methods: report 2 of the ISPOR value of information analysis emerging good practices task force&nbsp;», <i>Value in health</i>, vol. 23, n<sup>o</sup> 3, p. 277‑286, 2020.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Value%20of%20information%20analytical%20methods%3A%20report%202%20of%20the%20ISPOR%20value%20of%20information%20analysis%20emerging%20good%20practices%20task%20force&amp;rft.jtitle=Value%20in%20health&amp;rft.volume=23&amp;rft.issue=3&amp;rft.aufirst=Claire&amp;rft.aulast=Rothery&amp;rft.au=Claire%20Rothery&amp;rft.au=Mark%20Strong&amp;rft.au=Hendrik%20Erik%20Koffijberg&amp;rft.au=Anirban%20Basu&amp;rft.au=Salah%20Ghabri&amp;rft.au=Saskia%20Knies&amp;rft.au=James%20F%20Murray&amp;rft.au=Gillian%20D%20Sanders%20Schmidler&amp;rft.au=Lotte%20Steuten&amp;rft.au=Elisabeth%20Fenwick&amp;rft.date=2020&amp;rft.pages=277%E2%80%93286&amp;rft.spage=277&amp;rft.epage=286"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[8]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">S. Qu <i>et al.</i>, «&nbsp;Cost-effectiveness analysis of the prevention of mother-to-child transmission of HIV&nbsp;», <i>Infectious Diseases of Poverty</i>, vol. 11, n<sup>o</sup> 1, p. 68, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20analysis%20of%20the%20prevention%20of%20mother-to-child%20transmission%20of%20HIV&amp;rft.jtitle=Infectious%20Diseases%20of%20Poverty&amp;rft.volume=11&amp;rft.issue=1&amp;rft.aufirst=Shui-ling&amp;rft.aulast=Qu&amp;rft.au=Shui-ling%20Qu&amp;rft.au=Ai-ling%20Wang&amp;rft.au=Hong-mei%20Yin&amp;rft.au=Jin-qi%20Deng&amp;rft.au=Xiao-yan%20Wang&amp;rft.au=Ye-huan%20Yang&amp;rft.au=Xiao-ping%20Pan&amp;rft.au=Tong%20Zhang&amp;rft.date=2022&amp;rft.pages=68"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[9]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Paix, F. Thillays, M. Julian Biau, N. Vulquin, M. Sauleau, et G. Noël, «&nbsp;Cost-effectiveness analysis of radiosurgery and hypofractionated stereotactic radiotherapy in colorectal cancer brain metastases.&nbsp;», <i>Radiothérapie stéréotaxique des métastases cérébrales de mélanomes et de cancers colorectaux</i>, p. 101.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20analysis%20of%20radiosurgery%20and%20hypofractionated%20stereotactic%20radiotherapy%20in%20colorectal%20cancer%20brain%20metastases.&amp;rft.jtitle=Radioth%C3%A9rapie%20st%C3%A9r%C3%A9otaxique%20des%20m%C3%A9tastases%20c%C3%A9r%C3%A9brales%20de%20m%C3%A9lanomes%20et%20de%20cancers%20colorectaux&amp;rft.aufirst=Adrien&amp;rft.aulast=Paix&amp;rft.au=Adrien%20Paix&amp;rft.au=Fran%C3%A7ois%20Thillays&amp;rft.au=MD%20Julian%20Biau&amp;rft.au=No%C3%A9mie%20Vulquin&amp;rft.au=MD%20Sauleau&amp;rft.au=Georges%20No%C3%ABl&amp;rft.pages=101"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[10]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Paix, F. Thillays, F. Courtault-Deslandes, I. Popp, et G. Noël, «&nbsp;Cost-effectiveness analysis of radiosurgery and hypofractionated stereotactic radiotherapy in melanoma brain metastases.&nbsp;», <i>Radiothérapie stéréotaxique des métastases cérébrales de mélanomes et de cancers colorectaux</i>, p. 81.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20analysis%20of%20radiosurgery%20and%20hypofractionated%20stereotactic%20radiotherapy%20in%20melanoma%20brain%20metastases.&amp;rft.jtitle=Radioth%C3%A9rapie%20st%C3%A9r%C3%A9otaxique%20des%20m%C3%A9tastases%20c%C3%A9r%C3%A9brales%20de%20m%C3%A9lanomes%20et%20de%20cancers%20colorectaux&amp;rft.aufirst=Adrien&amp;rft.aulast=Paix&amp;rft.au=Adrien%20Paix&amp;rft.au=Fran%C3%A7ois%20Thillays&amp;rft.au=Flora%20Courtault-Deslandes&amp;rft.au=Ilinca%20Popp&amp;rft.au=Georges%20No%C3%ABl&amp;rft.pages=81"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[11]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Paix, G. Noel, P.-E. Falcoz, et P. Levy, «&nbsp;Cost-effectiveness analysis of stereotactic body radiotherapy and surgery for medically operable early stage non small cell lung cancer&nbsp;», <i>Radiotherapy and Oncology</i>, vol. 128, n<sup>o</sup> 3, p. 534‑540, 2018.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20analysis%20of%20stereotactic%20body%20radiotherapy%20and%20surgery%20for%20medically%20operable%20early%20stage%20non%20small%20cell%20lung%20cancer&amp;rft.jtitle=Radiotherapy%20and%20Oncology&amp;rft.volume=128&amp;rft.issue=3&amp;rft.aufirst=Adrien&amp;rft.aulast=Paix&amp;rft.au=Adrien%20Paix&amp;rft.au=Georges%20Noel&amp;rft.au=Pierre-Emmanuel%20Falcoz&amp;rft.au=Pierre%20Levy&amp;rft.date=2018&amp;rft.pages=534%E2%80%93540&amp;rft.spage=534&amp;rft.epage=540"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[12]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">T. B. Matanhire et S.-W. Lin, «&nbsp;An economic reappraisal of hepatitis B virus testing strategy for blood donors in Taiwan&nbsp;», <i>Vox Sanguinis</i>, vol. 116, n<sup>o</sup> 5, p. 564‑573, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=An%20economic%20reappraisal%20of%20hepatitis%20B%20virus%20testing%20strategy%20for%20blood%20donors%20in%20Taiwan&amp;rft.jtitle=Vox%20Sanguinis&amp;rft.volume=116&amp;rft.issue=5&amp;rft.aufirst=Tapiwa%20Blessing&amp;rft.aulast=Matanhire&amp;rft.au=Tapiwa%20Blessing%20Matanhire&amp;rft.au=Shi-Woei%20Lin&amp;rft.date=2021&amp;rft.pages=564%E2%80%93573&amp;rft.spage=564&amp;rft.epage=573"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[13]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J. Martikainen <i>et al.</i>, «&nbsp;Type 2 diabetes-related health economic impact associated with increased whole grains consumption among adults in Finland&nbsp;», <i>Nutrients</i>, vol. 13, n<sup>o</sup> 10, p. 3583, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Type%202%20diabetes-related%20health%20economic%20impact%20associated%20with%20increased%20whole%20grains%20consumption%20among%20adults%20in%20Finland&amp;rft.jtitle=Nutrients&amp;rft.volume=13&amp;rft.issue=10&amp;rft.aufirst=Janne&amp;rft.aulast=Martikainen&amp;rft.au=Janne%20Martikainen&amp;rft.au=Kari%20Jalkanen&amp;rft.au=Jari%20Heiskanen&amp;rft.au=Piia%20Lavikainen&amp;rft.au=Markku%20Peltonen&amp;rft.au=Tiina%20Laatikainen&amp;rft.au=Jaana%20Lindstr%C3%B6m&amp;rft.date=2021&amp;rft.pages=3583"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[14]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">N. Mafirakureva <i>et al.</i>, «&nbsp;Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan&nbsp;», <i>Journal of Viral Hepatitis</i>, vol. 28, n<sup>o</sup> 2, p. 268‑278, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20of%20screening%20and%20treatment%20using%20direct-acting%20antivirals%20for%20chronic%20Hepatitis%20C%20virus%20in%20a%20primary%20care%20setting%20in%20Karachi%2C%20Pakistan&amp;rft.jtitle=Journal%20of%20Viral%20Hepatitis&amp;rft.volume=28&amp;rft.issue=2&amp;rft.aufirst=Nyashadzaishe&amp;rft.aulast=Mafirakureva&amp;rft.au=Nyashadzaishe%20Mafirakureva&amp;rft.au=Aaron%20G%20Lim&amp;rft.au=Gul%20Ghuttai%20Khalid&amp;rft.au=Khawar%20Aslam&amp;rft.au=Linda%20Campbell&amp;rft.au=Hassaan%20Zahid&amp;rft.au=Rafael%20Van%20den%20Bergh&amp;rft.au=Gregoire%20Falq&amp;rft.au=Camille%20Fortas&amp;rft.au=Yves%20Wailly&amp;rft.au=undefined&amp;rft.date=2021&amp;rft.pages=268%E2%80%93278&amp;rft.spage=268&amp;rft.epage=278"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[15]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">X. Liang, X. Chen, H. Li, et Y. Li, «&nbsp;Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer&nbsp;», <i>Frontiers in Public Health</i>, vol. 11, 2023.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Tislelizumab%20plus%20chemotherapy%20is%20more%20cost-effective%20than%20chemotherapy%20alone%20as%20first-line%20therapy%20for%20advanced%20non-squamous%20non-small%20cell%20lung%20cancer&amp;rft.jtitle=Frontiers%20in%20Public%20Health&amp;rft.volume=11&amp;rft.aufirst=Xueyan&amp;rft.aulast=Liang&amp;rft.au=Xueyan%20Liang&amp;rft.au=Xiaoyu%20Chen&amp;rft.au=Huijuan%20Li&amp;rft.au=Yan%20Li&amp;rft.date=2023"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[16]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">X. Liang, X. Chen, H. Li, X. Liu, et Y. Li, «&nbsp;Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis&nbsp;», <i>Frontiers in Public Health</i>, vol. 11, 2023.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Sugemalimab%20plus%20chemotherapy%20vs.%20chemotherapy%20for%20metastatic%20non-small-cell%20lung%20cancer%3A%20A%20cost-effectiveness%20analysis&amp;rft.jtitle=Frontiers%20in%20Public%20Health&amp;rft.volume=11&amp;rft.aufirst=Xueyan&amp;rft.aulast=Liang&amp;rft.au=Xueyan%20Liang&amp;rft.au=Xiaoyu%20Chen&amp;rft.au=Huijuan%20Li&amp;rft.au=Xiaoxia%20Liu&amp;rft.au=Yan%20Li&amp;rft.date=2023"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[17]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Li, X. Liang, T. Yang, S. Guo, et X. Chen, «&nbsp;Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis&nbsp;», <i>Frontiers in Oncology</i>, p. 4987, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Pembrolizumab%20vs%20cemiplimab%20for%20the%20treatment%20of%20advanced%20non-small%20cell%20lung%20cancer%20with%20PD-L1%20expression%20levels%20of%20at%20least%2050%25%3A%20A%20network%20meta-analysis%20and%20cost-effectiveness%20analysis&amp;rft.jtitle=Frontiers%20in%20Oncology&amp;rft.aufirst=Yan&amp;rft.aulast=Li&amp;rft.au=Yan%20Li&amp;rft.au=Xueyan%20Liang&amp;rft.au=Tong%20Yang&amp;rft.au=Sitong%20Guo&amp;rft.au=Xiaoyu%20Chen&amp;rft.date=2022&amp;rft.pages=4987"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[18]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Li, X. Liang, H. Li, T. Yang, S. Guo, et X. Chen, «&nbsp;Nivolumab Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma: A Cost-Effectiveness Analysis&nbsp;», <i>Frontiers in Pharmacology</i>, p. 2661, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Nivolumab%20Versus%20Sorafenib%20as%20First-Line%20Therapy%20for%20Advanced%20Hepatocellular%20Carcinoma%3A%20A%20Cost-Effectiveness%20Analysis&amp;rft.jtitle=Frontiers%20in%20Pharmacology&amp;rft.aufirst=Yan&amp;rft.aulast=Li&amp;rft.au=Yan%20Li&amp;rft.au=Xueyan%20Liang&amp;rft.au=Huijuan%20Li&amp;rft.au=Tong%20Yang&amp;rft.au=Sitong%20Guo&amp;rft.au=Xiaoyu%20Chen&amp;rft.date=2022&amp;rft.pages=2661"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[19]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Li, X. Liang, H. Li, et X. Chen, «&nbsp;Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: A cost-effectiveness analysis&nbsp;», <i>Cancer</i>, vol. 128, n<sup>o</sup> 22, p. 3995‑4003, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Atezolizumab%20plus%20bevacizumab%20versus%20nivolumab%20as%20first-line%20treatment%20for%20advanced%20or%20unresectable%20hepatocellular%20carcinoma%3A%20A%20cost-effectiveness%20analysis&amp;rft.jtitle=Cancer&amp;rft.volume=128&amp;rft.issue=22&amp;rft.aufirst=Yan&amp;rft.aulast=Li&amp;rft.au=Yan%20Li&amp;rft.au=Xueyan%20Liang&amp;rft.au=Huijuan%20Li&amp;rft.au=Xiaoyu%20Chen&amp;rft.date=2022&amp;rft.pages=3995%E2%80%934003&amp;rft.spage=3995&amp;rft.epage=4003"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[20]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">C. A. Lemmon, E. C. Zabor, et N. A. Pennell, «&nbsp;Modeling the Cost-Effectiveness of Adjuvant Osimertinib for Patients with Resected EGFR-mutant Non-Small Cell Lung Cancer&nbsp;», <i>The Oncologist</i>, vol. 27, n<sup>o</sup> 5, p. 407‑413, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Modeling%20the%20Cost-Effectiveness%20of%20Adjuvant%20Osimertinib%20for%20Patients%20with%20Resected%20EGFR-mutant%20Non-Small%20Cell%20Lung%20Cancer&amp;rft.jtitle=The%20Oncologist&amp;rft.volume=27&amp;rft.issue=5&amp;rft.aufirst=Christopher%20A&amp;rft.aulast=Lemmon&amp;rft.au=Christopher%20A%20Lemmon&amp;rft.au=Emily%20C%20Zabor&amp;rft.au=Nathan%20A%20Pennell&amp;rft.date=2022&amp;rft.pages=407%E2%80%93413&amp;rft.spage=407&amp;rft.epage=413"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[21]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">N. J. Koech, «&nbsp;Cost Utility and Budget Impact Analysis of 5-fluorouracil and Capecitabine Based Regimens for Management of Colorectal Cancer at Kenyatta National Hospital&nbsp;», PhD Thesis, University of Nairobi, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adissertation&amp;rft.title=Cost%20Utility%20and%20Budget%20Impact%20Analysis%20of%205-fluorouracil%20and%20Capecitabine%20Based%20Regimens%20for%20Management%20of%20Colorectal%20Cancer%20at%20Kenyatta%20National%20Hospital&amp;rft.aufirst=Nancy%20J&amp;rft.aulast=Koech&amp;rft.au=Nancy%20J%20Koech&amp;rft.date=2022"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[22]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">R. Kandimalla <i>et al.</i>, «&nbsp;OCaMIR—A Noninvasive, Diagnostic Signature for Early-Stage Ovarian Cancer: A Multi-cohort Retrospective and Prospective StudyOCaMIR: A Diagnostic Signature for Ovarian Cancer&nbsp;», <i>Clinical Cancer Research</i>, vol. 27, n<sup>o</sup> 15, p. 4277‑4286, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=OCaMIR%E2%80%94A%20Noninvasive%2C%20Diagnostic%20Signature%20for%20Early-Stage%20Ovarian%20Cancer%3A%20A%20Multi-cohort%20Retrospective%20and%20Prospective%20StudyOCaMIR%3A%20A%20Diagnostic%20Signature%20for%20Ovarian%20Cancer&amp;rft.jtitle=Clinical%20Cancer%20Research&amp;rft.volume=27&amp;rft.issue=15&amp;rft.aufirst=Raju&amp;rft.aulast=Kandimalla&amp;rft.au=Raju%20Kandimalla&amp;rft.au=Wei%20Wang&amp;rft.au=Fan%20Yu&amp;rft.au=Nianxin%20Zhou&amp;rft.au=Feng%20Gao&amp;rft.au=Monique%20Spillman&amp;rft.au=Lucie%20Moukova&amp;rft.au=Ondrej%20Slaby&amp;rft.au=Bodour%20Salhia&amp;rft.au=Shengtao%20Zhou&amp;rft.au=undefined&amp;rft.date=2021&amp;rft.pages=4277%E2%80%934286&amp;rft.spage=4277&amp;rft.epage=4286"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[23]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J. P. Jansen, D. Incerti, et M. T. Linthicum, «&nbsp;Developing open-source models for the US health system: practical experiences and challenges to date with the open-source value project&nbsp;», <i>Pharmacoeconomics</i>, vol. 37, n<sup>o</sup> 11, p. 1313‑1320, 2019.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Developing%20open-source%20models%20for%20the%20US%20health%20system%3A%20practical%20experiences%20and%20challenges%20to%20date%20with%20the%20open-source%20value%20project&amp;rft.jtitle=Pharmacoeconomics&amp;rft.volume=37&amp;rft.issue=11&amp;rft.aufirst=Jeroen%20P&amp;rft.aulast=Jansen&amp;rft.au=Jeroen%20P%20Jansen&amp;rft.au=Devin%20Incerti&amp;rft.au=Mark%20T%20Linthicum&amp;rft.date=2019&amp;rft.pages=1313%E2%80%931320&amp;rft.spage=1313&amp;rft.epage=1320"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[24]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">F. Hofer, H.-U. Kauczor, et T. Stargardt, «&nbsp;Cost-utility analysis of a potential lung cancer screening program for a high-risk population in Germany: A modelling approach&nbsp;», <i>Lung Cancer</i>, vol. 124, p. 189‑198, 2018.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-utility%20analysis%20of%20a%20potential%20lung%20cancer%20screening%20program%20for%20a%20high-risk%20population%20in%20Germany%3A%20A%20modelling%20approach&amp;rft.jtitle=Lung%20Cancer&amp;rft.volume=124&amp;rft.aufirst=Florian&amp;rft.aulast=Hofer&amp;rft.au=Florian%20Hofer&amp;rft.au=Hans-Ulrich%20Kauczor&amp;rft.au=Tom%20Stargardt&amp;rft.date=2018&amp;rft.pages=189%E2%80%93198&amp;rft.spage=189&amp;rft.epage=198"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[25]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">M. Farraia <i>et al.</i>, «&nbsp;Cost-effectiveness analysis of house dust mite allergen immunotherapy in children with allergic asthma&nbsp;», <i>Allergy</i>, vol. 77, n<sup>o</sup> 9, p. 2688‑2698, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20analysis%20of%20house%20dust%20mite%20allergen%20immunotherapy%20in%20children%20with%20allergic%20asthma&amp;rft.jtitle=Allergy&amp;rft.volume=77&amp;rft.issue=9&amp;rft.aufirst=Mariana&amp;rft.aulast=Farraia&amp;rft.au=Mariana%20Farraia&amp;rft.au=In%C3%AAs%20Paci%C3%AAncia&amp;rft.au=Francisca%20Castro%20Mendes&amp;rft.au=Jo%C3%A3o%20Cavaleiro%20Rufo&amp;rft.au=Mohamed%20H.%20Shamji&amp;rft.au=Ioana%20Agache&amp;rft.au=Andr%C3%A9%20Moreira&amp;rft.date=2022&amp;rft.pages=2688%E2%80%932698&amp;rft.spage=2688&amp;rft.epage=2698"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[26]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Erfányuková, O. Gajdoš, V. Kamenskỳ, et M. Selčan, «&nbsp;Use of Various Health Technology Assessment Methods for Economic, Clinical and Safety Assessment&nbsp;», in <i>2019 E-Health and Bioengineering Conference (EHB)</i>, IEEE, 2019, p. 1‑4.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=proceeding&amp;rft.atitle=Use%20of%20Various%20Health%20Technology%20Assessment%20Methods%20for%20Economic%2C%20Clinical%20and%20Safety%20Assessment&amp;rft.btitle=2019%20E-Health%20and%20Bioengineering%20Conference%20(EHB)&amp;rft.publisher=IEEE&amp;rft.aufirst=Anna&amp;rft.aulast=Erf%C3%A1nyukov%C3%A1&amp;rft.au=Anna%20Erf%C3%A1nyukov%C3%A1&amp;rft.au=Ond%C5%99ej%20Gajdo%C5%A1&amp;rft.au=Vojt%C4%9Bch%20Kamensk%E1%BB%B3&amp;rft.au=Miroslav%20Sel%C4%8Dan&amp;rft.date=2019&amp;rft.pages=1%E2%80%934&amp;rft.spage=1&amp;rft.epage=4"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[27]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Carta et C. Conversano, «&nbsp;Cost utility analysis of Remdesivir and Dexamethasone treatment for hospitalised COVID-19 patients-a hypothetical study&nbsp;», <i>BMC Health Services Research</i>, vol. 21, n<sup>o</sup> 1, p. 1‑12, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost%20utility%20analysis%20of%20Remdesivir%20and%20Dexamethasone%20treatment%20for%20hospitalised%20COVID-19%20patients-a%20hypothetical%20study&amp;rft.jtitle=BMC%20Health%20Services%20Research&amp;rft.volume=21&amp;rft.issue=1&amp;rft.aufirst=Andrea&amp;rft.aulast=Carta&amp;rft.au=Andrea%20Carta&amp;rft.au=Claudio%20Conversano&amp;rft.date=2021&amp;rft.pages=1%E2%80%9312&amp;rft.spage=1&amp;rft.epage=12"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[28]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J. R. Beck et E. A. Handorf, «&nbsp;4 Markov Modeling in&nbsp;», <i>Pharmacoeconomics: From Theory to Practice</i>, p. 63, 2020.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=4%20Markov%20Modeling%20in&amp;rft.jtitle=Pharmacoeconomics%3A%20From%20Theory%20to%20Practice&amp;rft.aufirst=J%20Robert&amp;rft.aulast=Beck&amp;rft.au=J%20Robert%20Beck&amp;rft.au=Elizabeth%20A%20Handorf&amp;rft.date=2020&amp;rft.pages=63"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[29]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">K. Zarca <i>et al.</i>, «&nbsp;Cost-Utility Analysis of Transarterial Radioembolization With Yttrium-90 Resin Microspheres Compared With Sorafenib in Locally Advanced and Inoperable Hepatocellular Carcinoma&nbsp;», <i>Clinical Therapeutics</i>, vol. 43, n<sup>o</sup> 7, p. 1201‑1212, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-Utility%20Analysis%20of%20Transarterial%20Radioembolization%20With%20Yttrium-90%20Resin%20Microspheres%20Compared%20With%20Sorafenib%20in%20Locally%20Advanced%20and%20Inoperable%20Hepatocellular%20Carcinoma&amp;rft.jtitle=Clinical%20Therapeutics&amp;rft.volume=43&amp;rft.issue=7&amp;rft.aufirst=Kevin&amp;rft.aulast=Zarca&amp;rft.au=Kevin%20Zarca&amp;rft.au=Maroua%20Mimouni&amp;rft.au=Helena%20Pereira&amp;rft.au=Gilles%20Chatellier&amp;rft.au=Val%C3%A9rie%20Vilgrain&amp;rft.au=Isabelle%20Durand-Zaleski&amp;rft.au=Eric%20Assenat&amp;rft.au=Elisabeth%20Delhom-Christol&amp;rft.au=Boris%20Guiu&amp;rft.au=Alina%20D%20Ilonca&amp;rft.au=undefined&amp;rft.date=2021&amp;rft.pages=1201%E2%80%931212&amp;rft.spage=1201&amp;rft.epage=1212"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[30]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">J. Yukich <i>et al.</i>, «&nbsp;Projecting the impact of the COVID-19 pandemic on child marriage&nbsp;», <i>Journal of Adolescent Health</i>, vol. 69, n<sup>o</sup> 6, p. S23‑S30, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Projecting%20the%20impact%20of%20the%20COVID-19%20pandemic%20on%20child%20marriage&amp;rft.jtitle=Journal%20of%20Adolescent%20Health&amp;rft.volume=69&amp;rft.issue=6&amp;rft.aufirst=Joshua&amp;rft.aulast=Yukich&amp;rft.au=Joshua%20Yukich&amp;rft.au=Matt%20Worges&amp;rft.au=Anastasia%20J%20Gage&amp;rft.au=David%20R%20Hotchkiss&amp;rft.au=Annie%20Preaux&amp;rft.au=Colleen%20Murray&amp;rft.au=Claudia%20Cappa&amp;rft.date=2021&amp;rft.pages=S23%E2%80%93S30&amp;rft.spage=S23&amp;rft.epage=S30"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[31]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Xin <i>et al.</i>, «&nbsp;From spreadsheets to script: experiences from converting a Scottish cardiovascular disease policy model into R&nbsp;», <i>Applied health economics and health policy</i>, p. 1‑10, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=From%20spreadsheets%20to%20script%3A%20experiences%20from%20converting%20a%20Scottish%20cardiovascular%20disease%20policy%20model%20into%20R&amp;rft.jtitle=Applied%20health%20economics%20and%20health%20policy&amp;rft.aufirst=Yiqiao&amp;rft.aulast=Xin&amp;rft.au=Yiqiao%20Xin&amp;rft.au=Ewan%20Gray&amp;rft.au=Jose%20Antonio%20Robles-Zurita&amp;rft.au=Houra%20Haghpanahan&amp;rft.au=Robert%20Heggie&amp;rft.au=Ciaran%20Kohli-Lynch&amp;rft.au=Andrew%20Briggs&amp;rft.au=David%20A%20McAllister&amp;rft.au=Kenny%20D%20Lawson&amp;rft.au=Jim%20Lewsey&amp;rft.date=2022&amp;rft.pages=1%E2%80%9310&amp;rft.spage=1&amp;rft.epage=10"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[32]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Q. Xie, H. Zheng, Y. Chen, et X. Peng, «&nbsp;Cost-Effectiveness of Avelumab Maintenance Therapy Plus Best Supportive Care vs. Best Supportive Care Alone for Advanced or Metastatic Urothelial Carcinoma&nbsp;», <i>Frontiers in Public Health</i>, vol. 10, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-Effectiveness%20of%20Avelumab%20Maintenance%20Therapy%20Plus%20Best%20Supportive%20Care%20vs.%20Best%20Supportive%20Care%20Alone%20for%20Advanced%20or%20Metastatic%20Urothelial%20Carcinoma&amp;rft.jtitle=Frontiers%20in%20Public%20Health&amp;rft.volume=10&amp;rft.aufirst=Qian&amp;rft.aulast=Xie&amp;rft.au=Qian%20Xie&amp;rft.au=Hanrui%20Zheng&amp;rft.au=Ye%20Chen&amp;rft.au=Xingchen%20Peng&amp;rft.date=2022"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[33]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">H. Weiting <i>et al.</i>, «&nbsp;The clinical value and cost-effectiveness of treatments for patients with coronary artery disease&nbsp;», <i>Health Economics Review</i>, vol. 12, n<sup>o</sup> 1, p. 1‑8, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=The%20clinical%20value%20and%20cost-effectiveness%20of%20treatments%20for%20patients%20with%20coronary%20artery%20disease&amp;rft.jtitle=Health%20Economics%20Review&amp;rft.volume=12&amp;rft.issue=1&amp;rft.aufirst=Huang&amp;rft.aulast=Weiting&amp;rft.au=Huang%20Weiting&amp;rft.au=Alwin%20Zhang%20Yaoxian&amp;rft.au=Yeo%20Khung%20Keong&amp;rft.au=Shao%20Wei%20Lam&amp;rft.au=Lau%20Yee%20How&amp;rft.au=Anders%20Olof%20Sahl%C3%A9n&amp;rft.au=Ahmadreza%20Pourghaderi&amp;rft.au=Matthew%20Che&amp;rft.au=Chua%20Siang%20Jin%20Terrance&amp;rft.au=Nicholas%20Graves&amp;rft.date=2022&amp;rft.pages=1%E2%80%938&amp;rft.spage=1&amp;rft.epage=8"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[34]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">R. Vadia, N. Malyar, et T. Stargardt, «&nbsp;Cost-utility analysis of early versus delayed endovascular intervention in critical limb-threatening ischemia (CLTI) patients with rest-pain&nbsp;», <i>Journal of Vascular Surgery</i>, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-utility%20analysis%20of%20early%20versus%20delayed%20endovascular%20intervention%20in%20critical%20limb-threatening%20ischemia%20(CLTI)%20patients%20with%20rest-pain&amp;rft.jtitle=Journal%20of%20Vascular%20Surgery&amp;rft.aufirst=Rucha&amp;rft.aulast=Vadia&amp;rft.au=Rucha%20Vadia&amp;rft.au=Nasser%20Malyar&amp;rft.au=Tom%20Stargardt&amp;rft.date=2022"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[35]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">R. Vadia, «&nbsp;PMD38 Cost-Effectiveness of Timely Endovascular Intervention VS. Delayed Intervention By Conservative Treatment in Patients with Critical LIMB Ischemia (CLI)&nbsp;», <i>Value in Health</i>, vol. 23, p. S582, 2020.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=PMD38%20Cost-Effectiveness%20of%20Timely%20Endovascular%20Intervention%20VS.%20Delayed%20Intervention%20By%20Conservative%20Treatment%20in%20Patients%20with%20Critical%20LIMB%20Ischemia%20(CLI)&amp;rft.jtitle=Value%20in%20Health&amp;rft.volume=23&amp;rft.aufirst=R&amp;rft.aulast=Vadia&amp;rft.au=R%20Vadia&amp;rft.date=2020&amp;rft.pages=S582"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[36]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">K. Sugiura, K. Suzuki, T. Umeyama, K. Omagari, T. Hashimoto, et A. Tamura, «&nbsp;Cost-effectiveness analysis of initial nonoperative management versus emergency laparoscopic appendectomy for acute complicated appendicitis&nbsp;», <i>BMC Health Services Research</i>, vol. 20, p. 1‑10, 2020.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20analysis%20of%20initial%20nonoperative%20management%20versus%20emergency%20laparoscopic%20appendectomy%20for%20acute%20complicated%20appendicitis&amp;rft.jtitle=BMC%20Health%20Services%20Research&amp;rft.volume=20&amp;rft.aufirst=Kiyoaki&amp;rft.aulast=Sugiura&amp;rft.au=Kiyoaki%20Sugiura&amp;rft.au=Keiichi%20Suzuki&amp;rft.au=Tomoshige%20Umeyama&amp;rft.au=Kenshi%20Omagari&amp;rft.au=Takeo%20Hashimoto&amp;rft.au=Akihiko%20Tamura&amp;rft.date=2020&amp;rft.pages=1%E2%80%9310&amp;rft.spage=1&amp;rft.epage=10"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[37]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">K. Sugiura <i>et al.</i>, «&nbsp;Cost-effectiveness of TAS-102 plus bevacizumab versus TAS-102 monotherapy in patients with metastatic colorectal cancer&nbsp;», <i>BMC gastroenterology</i>, vol. 21, n<sup>o</sup> 1, p. 1‑9, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20of%20TAS-102%20plus%20bevacizumab%20versus%20TAS-102%20monotherapy%20in%20patients%20with%20metastatic%20colorectal%20cancer&amp;rft.jtitle=BMC%20gastroenterology&amp;rft.volume=21&amp;rft.issue=1&amp;rft.aufirst=Kiyoaki&amp;rft.aulast=Sugiura&amp;rft.au=Kiyoaki%20Sugiura&amp;rft.au=Yuki%20Seo&amp;rft.au=Takayuki%20Takahashi&amp;rft.au=Hideyuki%20Tokura&amp;rft.au=Yasuhiro%20Ito&amp;rft.au=Motomu%20Tanaka&amp;rft.au=Norihiro%20Kishida&amp;rft.au=Yusuke%20Nishi&amp;rft.au=Yoshihiko%20Onishi&amp;rft.au=Hikaru%20Aoki&amp;rft.date=2021&amp;rft.pages=1%E2%80%939&amp;rft.spage=1&amp;rft.epage=9"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[38]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Shi <i>et al.</i>, «&nbsp;Comparing the cost-effectiveness of sintilimab+ pemetrexed plus platinum and pemetrexed plus platinum alone as a first-line therapy for Chinese patients with nonsquamous non-small cell lung cancer&nbsp;», 2023.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Comparing%20the%20cost-effectiveness%20of%20sintilimab%2B%20pemetrexed%20plus%20platinum%20and%20pemetrexed%20plus%20platinum%20alone%20as%20a%20first-line%20therapy%20for%20Chinese%20patients%20with%20nonsquamous%20non-small%20cell%20lung%20cancer&amp;rft.aufirst=Yafei&amp;rft.aulast=Shi&amp;rft.au=Yafei%20Shi&amp;rft.au=Di%20Qian&amp;rft.au=Yanhui%20Li&amp;rft.au=Wei%20Chen&amp;rft.au=Mingming%20Bo&amp;rft.au=Mingyu%20Zhang&amp;rft.au=Jianglei%20Shi&amp;rft.au=Bei%20Jia&amp;rft.au=Yuanyuan%20Dai&amp;rft.au=Guohui%20Li&amp;rft.date=2023"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[39]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Ruiz-Patiño <i>et al.</i>, «&nbsp;Mortality and advanced support requirement for patients with cancer with COVID-19: a mathematical dynamic model for Latin America&nbsp;», <i>JCO global oncology</i>, vol. 6, p. 752‑760, 2020.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mortality%20and%20advanced%20support%20requirement%20for%20patients%20with%20cancer%20with%20COVID-19%3A%20a%20mathematical%20dynamic%20model%20for%20Latin%20America&amp;rft.jtitle=JCO%20global%20oncology&amp;rft.volume=6&amp;rft.aufirst=Alejandro&amp;rft.aulast=Ruiz-Pati%C3%B1o&amp;rft.au=Alejandro%20Ruiz-Pati%C3%B1o&amp;rft.au=Oscar%20Arrieta&amp;rft.au=Luis%20E%20Pino&amp;rft.au=Christian%20Rolfo&amp;rft.au=Luisa%20Ricaurte&amp;rft.au=Gonzalo%20Recondo&amp;rft.au=Zyanya-Lucia%20Zatarain-Barron&amp;rft.au=Luis%20Corrales&amp;rft.au=Claudio%20Mart%C3%ADn&amp;rft.au=Feliciano%20Barr%C3%B3n&amp;rft.au=undefined&amp;rft.date=2020&amp;rft.pages=752%E2%80%93760&amp;rft.spage=752&amp;rft.epage=760"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[40]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. G. Ruiz <i>et al.</i>, «&nbsp;Cost-Effectiveness of the COVID-19 test, trace and isolate program in Colombia&nbsp;», <i>The Lancet Regional Health-Americas</i>, vol. 6, p. 100109, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-Effectiveness%20of%20the%20COVID-19%20test%2C%20trace%20and%20isolate%20program%20in%20Colombia&amp;rft.jtitle=The%20Lancet%20Regional%20Health-Americas&amp;rft.volume=6&amp;rft.aufirst=Yenny%20Guzm%C3%A1n&amp;rft.aulast=Ruiz&amp;rft.au=Yenny%20Guzm%C3%A1n%20Ruiz&amp;rft.au=Andres%20I%20Vecino-Ortiz&amp;rft.au=Nicol%C3%A1s%20Guzman-Tordecilla&amp;rft.au=Rolando%20Enrique%20Pe%C3%B1aloza-Quintero&amp;rft.au=Juli%C3%A1n%20A%20Fern%C3%A1ndez-Ni%C3%B1o&amp;rft.au=Maylen%20Rojas-Botero&amp;rft.au=Fernando%20Ruiz%20Gomez&amp;rft.au=Sean%20D%20Sullivan&amp;rft.au=Antonio%20J%20Trujillo&amp;rft.date=2022&amp;rft.pages=100109"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[41]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">C. Ramamurthy, E. A. Handorf, A. F. Correa, J. R. Beck, et D. M. Geynisman, «&nbsp;Cost-effectiveness of abiraterone versus docetaxel in the treatment of metastatic hormone naïve prostate cancer&nbsp;», in <i>Urologic Oncology: Seminars and Original Investigations</i>, Elsevier, 2019, p. 688‑695.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=proceeding&amp;rft.atitle=Cost-effectiveness%20of%20abiraterone%20versus%20docetaxel%20in%20the%20treatment%20of%20metastatic%20hormone%20na%C3%AFve%20prostate%20cancer&amp;rft.btitle=Urologic%20Oncology%3A%20Seminars%20and%20Original%20Investigations&amp;rft.publisher=Elsevier&amp;rft.aufirst=Chethan&amp;rft.aulast=Ramamurthy&amp;rft.au=Chethan%20Ramamurthy&amp;rft.au=Elizabeth%20A%20Handorf&amp;rft.au=Andres%20F%20Correa&amp;rft.au=J%20Robert%20Beck&amp;rft.au=Daniel%20M%20Geynisman&amp;rft.date=2019&amp;rft.pages=688%E2%80%93695&amp;rft.spage=688&amp;rft.epage=695"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[42]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">S. Plavinskiy et P. I. Shabalkin, «&nbsp;Evaluation of the clinical and economic effectiveness of interferon-gamma in the treatment of tuberculosis&nbsp;», <i>Epidemiology and Infectious Diseases</i>, vol. 22, n<sup>o</sup> 6, p. 276‑280, 2017.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Evaluation%20of%20the%20clinical%20and%20economic%20effectiveness%20of%20interferon-gamma%20in%20the%20treatment%20of%20tuberculosis&amp;rft.jtitle=Epidemiology%20and%20Infectious%20Diseases&amp;rft.volume=22&amp;rft.issue=6&amp;rft.aufirst=SL&amp;rft.aulast=Plavinskiy&amp;rft.au=SL%20Plavinskiy&amp;rft.au=Pavel%20I%20Shabalkin&amp;rft.date=2017&amp;rft.pages=276%E2%80%93280&amp;rft.spage=276&amp;rft.epage=280"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[43]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">T. Pierse, S. O’Neill, S. F. Dinneen, et C. O’Neill, «&nbsp;A simulation study of the economic and health impact of a diabetes prevention programme in Ireland&nbsp;», <i>Diabetic Medicine</i>, vol. 38, n<sup>o</sup> 6, p. e14540, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=A%20simulation%20study%20of%20the%20economic%20and%20health%20impact%20of%20a%20diabetes%20prevention%20programme%20in%20Ireland&amp;rft.jtitle=Diabetic%20Medicine&amp;rft.volume=38&amp;rft.issue=6&amp;rft.aufirst=Tom&amp;rft.aulast=Pierse&amp;rft.au=Tom%20Pierse&amp;rft.au=Stephen%20O'Neill&amp;rft.au=Sean%20F%20Dinneen&amp;rft.au=Ciaran%20O'Neill&amp;rft.date=2021&amp;rft.pages=e14540"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[44]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">C. Perret, L. Perrier, M. Castex, et C. Acquadro, «&nbsp;Proqolid database: evolution of content, structure, and functionalities (2012-2016)-integration in eprovide, a new online platform dedicated to clinical outcome assessment (Coa) research&nbsp;», <i>Value in Health</i>, vol. 19, n<sup>o</sup> 7, p. A369, 2016.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Proqolid%20database%3A%20evolution%20of%20content%2C%20structure%2C%20and%20functionalities%20(2012-2016)-integration%20in%20eprovide%2C%20a%20new%20online%20platform%20dedicated%20to%20clinical%20outcome%20assessment%20(Coa)%20research&amp;rft.jtitle=Value%20in%20Health&amp;rft.volume=19&amp;rft.issue=7&amp;rft.aufirst=C%C3%A9cile&amp;rft.aulast=Perret&amp;rft.au=C%C3%A9cile%20Perret&amp;rft.au=L%20Perrier&amp;rft.au=Myl%C3%A8ne%20Castex&amp;rft.au=Catherine%20Acquadro&amp;rft.date=2016&amp;rft.pages=A369"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[45]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">M.-T. Pandi, M. Koromina, G. Vonitsanos, P. J. van der&nbsp;Spek, G. P. Patrinos, et C. Mitropoulou, «&nbsp;Development of an optimized and generic cost-utility model for analyzing genome-guided treatment data&nbsp;», <i>Pharmacological Research</i>, vol. 178, p. 106187, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Development%20of%20an%20optimized%20and%20generic%20cost-utility%20model%20for%20analyzing%20genome-guided%20treatment%20data&amp;rft.jtitle=Pharmacological%20Research&amp;rft.volume=178&amp;rft.aufirst=Maria-Theodora&amp;rft.aulast=Pandi&amp;rft.au=Maria-Theodora%20Pandi&amp;rft.au=Maria%20Koromina&amp;rft.au=Gerasimos%20Vonitsanos&amp;rft.au=Peter%20J%20van%20der%20Spek&amp;rft.au=George%20P%20Patrinos&amp;rft.au=Christina%20Mitropoulou&amp;rft.date=2022&amp;rft.pages=106187"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[46]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">B. K. Njuguna, «&nbsp;Assessment of Expenditure and Budget Impact Analysis of Post-kidney Transplant Care at Kenyatta National Hospital&nbsp;», PhD Thesis, University of Nairobi, 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adissertation&amp;rft.title=Assessment%20of%20Expenditure%20and%20Budget%20Impact%20Analysis%20of%20Post-kidney%20Transplant%20Care%20at%20Kenyatta%20National%20Hospital&amp;rft.aufirst=Bernard%20K&amp;rft.aulast=Njuguna&amp;rft.au=Bernard%20K%20Njuguna&amp;rft.date=2022"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[47]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">N. Mason, J. Kenworthy, R. Akehurst, W. Sullivan, et W. Dunlop, «&nbsp;An Investigation Into Open-Source Modelling In Health Economics: Opportunities And Challenges&nbsp;», <i>Value in Health</i>, vol. 19, n<sup>o</sup> 7, p. A369, 2016.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=An%20Investigation%20Into%20Open-Source%20Modelling%20In%20Health%20Economics%3A%20Opportunities%20And%20Challenges&amp;rft.jtitle=Value%20in%20Health&amp;rft.volume=19&amp;rft.issue=7&amp;rft.aufirst=N&amp;rft.aulast=Mason&amp;rft.au=N%20Mason&amp;rft.au=JJ%20Kenworthy&amp;rft.au=R%20Akehurst&amp;rft.au=W%20Sullivan&amp;rft.au=W%20Dunlop&amp;rft.date=2016&amp;rft.pages=A369"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[48]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">S. Jones, N. White, T. Holt, et N. Graves, «&nbsp;Cost-effectiveness analysis of hydrogel spacer for rectal toxicity reduction in prostate external beam radiotherapy&nbsp;», <i>Journal of Medical Imaging and Radiation Oncology</i>, vol. 65, n<sup>o</sup> 7, p. 931‑939, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20analysis%20of%20hydrogel%20spacer%20for%20rectal%20toxicity%20reduction%20in%20prostate%20external%20beam%20radiotherapy&amp;rft.jtitle=Journal%20of%20Medical%20Imaging%20and%20Radiation%20Oncology&amp;rft.volume=65&amp;rft.issue=7&amp;rft.aufirst=Scott&amp;rft.aulast=Jones&amp;rft.au=Scott%20Jones&amp;rft.au=Nicole%20White&amp;rft.au=Tanya%20Holt&amp;rft.au=Nicholas%20Graves&amp;rft.date=2021&amp;rft.pages=931%E2%80%93939&amp;rft.spage=931&amp;rft.epage=939"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[49]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">W. Jia, W. Xin, S. Jing, et K. Qin, «&nbsp;Cost-effectiveness of sintilimab plus bevacizumab biosimilar versus sorafenib for unresectable hepatocellular carcinoma&nbsp;», 2022.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20of%20sintilimab%20plus%20bevacizumab%20biosimilar%20versus%20sorafenib%20for%20unresectable%20hepatocellular%20carcinoma&amp;rft.aufirst=Wang&amp;rft.aulast=Jia&amp;rft.au=Wang%20Jia&amp;rft.au=Wen%20Xin&amp;rft.au=Su%20Jing&amp;rft.au=Kan%20Qin&amp;rft.date=2022"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[50]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">N. Green, F. Lamrock, N. Naylor, J. Williams, et A. Briggs, «&nbsp;Health Economic Evaluation Using Markov Models in R for Microsoft Excel Users: A Tutorial&nbsp;», <i>PharmacoEconomics</i>, vol. 41, n<sup>o</sup> 1, p. 5‑19, 2023.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Health%20Economic%20Evaluation%20Using%20Markov%20Models%20in%20R%20for%20Microsoft%20Excel%20Users%3A%20A%20Tutorial&amp;rft.jtitle=PharmacoEconomics&amp;rft.volume=41&amp;rft.issue=1&amp;rft.aufirst=Nathan&amp;rft.aulast=Green&amp;rft.au=Nathan%20Green&amp;rft.au=Felicity%20Lamrock&amp;rft.au=Nichola%20Naylor&amp;rft.au=Jack%20Williams&amp;rft.au=Andrew%20Briggs&amp;rft.date=2023&amp;rft.pages=5%E2%80%9319&amp;rft.spage=5&amp;rft.epage=19"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[51]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">E. A. Gordeeva, N. P. Volkov, N. Y. Orudjev, N. A. Chernaya, et M. Y. Frolov, «&nbsp;PHARMACOECONOMICAL ASPECTS OF PARANOID SCHIZOPHRENIA TREATMENT USING COMBINED THERAPY WITH TYPICAL AND ATYPICAL NEUROLEPTICS&nbsp;», <i>Neurology Bulletin</i>, vol. 50, n<sup>o</sup> 2, p. 107‑108, 2018.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=PHARMACOECONOMICAL%20ASPECTS%20OF%20PARANOID%20SCHIZOPHRENIA%20TREATMENT%20USING%20COMBINED%20THERAPY%20WITH%20TYPICAL%20AND%20ATYPICAL%20NEUROLEPTICS&amp;rft.jtitle=Neurology%20Bulletin&amp;rft.volume=50&amp;rft.issue=2&amp;rft.aufirst=Ekaterina%20A&amp;rft.aulast=Gordeeva&amp;rft.au=Ekaterina%20A%20Gordeeva&amp;rft.au=Nikita%20P%20Volkov&amp;rft.au=Nazim%20Ya%20Orudjev&amp;rft.au=Natalya%20A%20Chernaya&amp;rft.au=Maxim%20Yu%20Frolov&amp;rft.date=2018&amp;rft.pages=107%E2%80%93108&amp;rft.spage=107&amp;rft.epage=108"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[52]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Filipović-Pierucci, K. Zarca, et I. Durand-Zaleski, «&nbsp;Markov models for health economic evaluations: the R package heemod&nbsp;», <i>arXiv preprint arXiv:1702.03252</i>, 2017.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Markov%20models%20for%20health%20economic%20evaluations%3A%20the%20R%20package%20heemod&amp;rft.jtitle=arXiv%20preprint%20arXiv%3A1702.03252&amp;rft.aufirst=Antoine&amp;rft.aulast=Filipovi%C4%87-Pierucci&amp;rft.au=Antoine%20Filipovi%C4%87-Pierucci&amp;rft.au=Kevin%20Zarca&amp;rft.au=Isabelle%20Durand-Zaleski&amp;rft.date=2017"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[53]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">A. Filipovic-Pierucci, K. Zarca, et I. Durand-Zaleski, «&nbsp;Markov models for health economic evaluation modelling in r with the heemod package&nbsp;», <i>Value in Health</i>, vol. 19, n<sup>o</sup> 7, p. A369, 2016.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Markov%20models%20for%20health%20economic%20evaluation%20modelling%20in%20r%20with%20the%20heemod%20package&amp;rft.jtitle=Value%20in%20Health&amp;rft.volume=19&amp;rft.issue=7&amp;rft.aufirst=A&amp;rft.aulast=Filipovic-Pierucci&amp;rft.au=A%20Filipovic-Pierucci&amp;rft.au=K%20Zarca&amp;rft.au=I%20Durand-Zaleski&amp;rft.date=2016&amp;rft.pages=A369"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[54]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">E. J. Dasbach et E. H. Elbasha, «&nbsp;Verification of decision-analytic models for health economic evaluations: an overview&nbsp;», <i>Pharmacoeconomics</i>, vol. 35, n<sup>o</sup> 7, p. 673‑683, 2017.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Verification%20of%20decision-analytic%20models%20for%20health%20economic%20evaluations%3A%20an%20overview&amp;rft.jtitle=Pharmacoeconomics&amp;rft.volume=35&amp;rft.issue=7&amp;rft.aufirst=Erik%20J&amp;rft.aulast=Dasbach&amp;rft.au=Erik%20J%20Dasbach&amp;rft.au=Elamin%20H%20Elbasha&amp;rft.date=2017&amp;rft.pages=673%E2%80%93683&amp;rft.spage=673&amp;rft.epage=683"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[55]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Cai, W. Hui, M. Zhu, M. Zhang, Z. Gao, et H. Wu, «&nbsp;Cost-Effectiveness Analysis of Pembrolizumab Plus Pemetrexed and Platinum Versus Chemotherapy Alone as First-Line Treatment in Metastatic Non-Squamous Non–Small Cell Lung Cancer: A Reconstruction of Partitioned Survival Model Based on Time Dependent Pricing Mechanism of Patient Assistance Program&nbsp;», <i>Frontiers in Oncology</i>, p. 4982, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-Effectiveness%20Analysis%20of%20Pembrolizumab%20Plus%20Pemetrexed%20and%20Platinum%20Versus%20Chemotherapy%20Alone%20as%20First-Line%20Treatment%20in%20Metastatic%20Non-Squamous%20Non%E2%80%93Small%20Cell%20Lung%20Cancer%3A%20A%20Reconstruction%20of%20Partitioned%20Survival%20Model%20Based%20on%20Time%20Dependent%20Pricing%20Mechanism%20of%20Patient%20Assistance%20Program&amp;rft.jtitle=Frontiers%20in%20Oncology&amp;rft.aufirst=Yuanyi&amp;rft.aulast=Cai&amp;rft.au=Yuanyi%20Cai&amp;rft.au=Wen%20Hui&amp;rft.au=Min%20Zhu&amp;rft.au=Mingyue%20Zhang&amp;rft.au=Zhixiang%20Gao&amp;rft.au=Huazhang%20Wu&amp;rft.date=2021&amp;rft.pages=4982"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[56]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">Y. Shi <i>et al.</i>, «&nbsp;Cost-effectiveness of pembrolizumab versus docetaxel as second-line treatment of non-small cell lung cancer in China&nbsp;», <i>Annals of Translational Medicine</i>, vol. 9, n<sup>o</sup> 18, 2021.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Cost-effectiveness%20of%20pembrolizumab%20versus%20docetaxel%20as%20second-line%20treatment%20of%20non-small%20cell%20lung%20cancer%20in%20China&amp;rft.jtitle=Annals%20of%20Translational%20Medicine&amp;rft.volume=9&amp;rft.issue=18&amp;rft.aufirst=Yafei&amp;rft.aulast=Shi&amp;rft.au=Yafei%20Shi&amp;rft.au=Wei%20Chen&amp;rft.au=Yujun%20Zhang&amp;rft.au=Mingming%20Bo&amp;rft.au=Chunyu%20Li&amp;rft.au=Mingyu%20Zhang&amp;rft.au=Guohui%20Li&amp;rft.date=2021"></span>
  <div class="csl-entry" style="clear: left; ">
    <div class="csl-left-margin" style="float: left; padding-right: 0.5em;text-align: right; width: 2em;">[57]</div><div class="csl-right-inline" style="margin: 0 .4em 0 2.5em;">H. Jalal, P. Pechlivanoglou, E. Krijkamp, F. Alarid-Escudero, E. Enns, et M. M. Hunink, «&nbsp;An overview of R in health decision sciences&nbsp;», <i>Medical decision making</i>, vol. 37, n<sup>o</sup> 7, p. 735‑746, 2017.</div>
  </div>
  <span class="Z3988" title="url_ver=Z39.88-2004&amp;ctx_ver=Z39.88-2004&amp;rfr_id=info%3Asid%2Fzotero.org%3A2&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=An%20overview%20of%20R%20in%20health%20decision%20sciences&amp;rft.jtitle=Medical%20decision%20making&amp;rft.volume=37&amp;rft.issue=7&amp;rft.aufirst=Hawre&amp;rft.aulast=Jalal&amp;rft.au=Hawre%20Jalal&amp;rft.au=Petros%20Pechlivanoglou&amp;rft.au=Eline%20Krijkamp&amp;rft.au=Fernando%20Alarid-Escudero&amp;rft.au=Eva%20Enns&amp;rft.au=MG%20Myriam%20Hunink&amp;rft.date=2017&amp;rft.pages=735%E2%80%93746&amp;rft.spage=735&amp;rft.epage=746"></span>
</div></body>
</html>
